Literature DB >> 23443343

SETBP1 mutations in 658 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia and secondary acute myeloid leukemias.

F Damm, R Itzykson, O Kosmider, N Droin, A Renneville, V Chesnais, V Gelsi-Boyer, S de Botton, N Vey, C Preudhomme, A Clavert, E Delabesse, S Park, D Birnbaum, M Fontenay, O A Bernard, E Solary.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23443343     DOI： 10.1038/leu.2013.35

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  56 in total

1.  Subclonal mutations in SETBP1 confer a poor prognosis in juvenile myelomonocytic leukemia.

Authors:  Elliot Stieglitz; Camille B Troup; Laura C Gelston; John Haliburton; Eric D Chow; Kristie B Yu; Jon Akutagawa; Amaro N Taylor-Weiner; Y Lucy Liu; Yong-Dong Wang; Kyle Beckman; Peter D Emanuel; Benjamin S Braun; Adam Abate; Robert B Gerbing; Todd A Alonzo; Mignon L Loh
Journal:  Blood       Date:  2014-11-13       Impact factor: 22.113

Review 2.  Next-generation sequencing-based panel testing for myeloid neoplasms.

Authors:  Frank C Kuo; Fei Dong
Journal:  Curr Hematol Malig Rep       Date:  2015-06       Impact factor: 3.952

Review 3.  Somatic SETBP1 mutations in myeloid neoplasms.

Authors:  Hideki Makishima
Journal:  Int J Hematol       Date:  2017-04-26       Impact factor: 2.490

4.  I walk the line: how to tell MDS from other bone marrow failure conditions.

Authors:  Lukasz P Gondek; Amy E DeZern
Journal:  Curr Hematol Malig Rep       Date:  2014-12       Impact factor: 3.952

5.  Myeloid progenitors with PTPN11 and nonRAS pathway gene mutations are refractory to treatment with 6-mercaptopurine in juvenile myelomonocytic leukemia.

Authors:  K Matsuda; Y Nakazawa; C Iwashita; T Kurata; K Hirabayashi; S Saito; M Tanaka; K Yoshikawa; R Yanagisawa; K Sakashita; S Sasaki; T Honda; K Koike
Journal:  Leukemia       Date:  2014-02-05       Impact factor: 11.528

6.  SETBP1 mutations in 106 patients with therapy-related myeloid neoplasms.

Authors:  Emiliano Fabiani; Giulia Falconi; Luana Fianchi; Marianna Criscuolo; Giuseppe Leone; Maria Teresa Voso
Journal:  Haematologica       Date:  2014-06-06       Impact factor: 9.941

Review 7.  Integrating genetics and epigenetics in myelodysplastic syndromes: advances in pathogenesis and disease evolution.

Authors:  Guillermo Montalbán Bravo; Elinor Lee; Bryan Merchan; Hagop M Kantarjian; Guillermo García-Manero
Journal:  Br J Haematol       Date:  2014-06-05       Impact factor: 6.998

Review 8.  Chronic myelomonocytic leukemia prognostic classification and management: evidence base and current practice.

Authors:  Dorothée Selimoglu-Buet; Eric Solary
Journal:  Curr Hematol Malig Rep       Date:  2014-12       Impact factor: 3.952

9.  Clonality of neutrophilia associated with plasma cell neoplasms: report of a SETBP1 mutation and analysis of a single institution series.

Authors:  Brett Stevens; Julia Maxson; Jeffrey Tyner; Clayton A Smith; Jonathan A Gutman; William Robinson; Craig T Jordan; Choon-Kee Lee; Karen Swisshelm; Jennifer Tobin; Qi Wei; Jeffrey Schowinsky; Sean Rinella; Hea Gie Lee; Daniel A Pollyea
Journal:  Leuk Lymphoma       Date:  2015-10-27

10.  Antagonism of SET using OP449 enhances the efficacy of tyrosine kinase inhibitors and overcomes drug resistance in myeloid leukemia.

Authors:  Anupriya Agarwal; Ryan J MacKenzie; Raffaella Pippa; Christopher A Eide; Jessica Oddo; Jeffrey W Tyner; Rosalie Sears; Michael P Vitek; María D Odero; Dale J Christensen; Brian J Druker
Journal:  Clin Cancer Res       Date:  2014-01-16       Impact factor: 12.531
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.